Late-breaking poster presentations show HCB101's favorable safety, strong receptor occupancy, and p...
HCB301 is a first-in-class tri-specific immunotherapy targeting SIRPα-CD47, PD-1/PD-L1, and TGFβ; i...
FACO 2025 presentation highlights HCB101's favorable safety, strong receptor occupancy, and confirm...
* Prestigious peer-review validates HCB101's differentiated mechanism and translational strength....
TAIPEI and SHANGHAI and SAN FRANCISCO, Oct. 21, 2025 /PRNewswire/ -- HanchorBio today announced th...
Presentations highlight HCB101's differentiated profile and introduce first preclinical data from H...
TAIPEI and SHANGHAI and SAN FRANCISCO, July 1, 2025 /PRNewswire/ -- HanchorBio Inc. (7827.TWO), a g...
Interim data on the cancer treatment shows robust potential for balancing efficacy and safety TAIP...